Incyte’s Bile Duct Cancer Drug Wins FDA Approval [Yahoo! Finance News]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance News
Incyte INCYPemazyre is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response DOR).“INCY shares have rallied of late, and we maintain a Neutral rating and $79 PT based on our view that meaningful catalysts for the shares are unlikely until 2021” commented Mizuho Securities’Mara GoldsteinThe analyst added that “the combination of low-risk revenue stream in JAKAFI and solid cash position is likely leading investors to view shares as a relative safe haven in the current market environment.”She believes that Pemazyre has a U.S. & E.U. market opportunity of approximately $800 million, and notes that the drug enjoys a best-in-class safety profile.According to Goldstein, the approval “is incrementally positive for shares, and we see this as a first step in the pursuit of more meaningful commercial opportunities such as urothelial cancer we estimate a U.S. and E.U. addressable market
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Trevi Therapeutics appoints new CFO [Seeking Alpha]Seeking Alpha
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and UnderstandingBusiness Wire
- Incyte Appoints Richard Hoffman as Executive Vice President and General CounselBusiness Wire
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- INCY's page on the SEC website